A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency

NCT00314938

Last updated date
Study Location
Pfizer Investigational Site
Brussel, , 1090, Belgium
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Growth Hormone Deficiency
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-12 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 1.Male and female children with a minimum age of 6 years

- 2. Prepubertal as defined by Tanner staging

- 3. Growth hormone deficiency

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- 1. PGHD patients with uncontrolled pituitary tumor growth


- 2. Tumors within 3 mm of the optic chiasm


- 3. Serum ALT and/or AST >= 1.5 times the upper limit of normal range

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Growth Hormone DeficiencyCross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects
NCT01112865
  1. Brno - mesto,
  2. Olomouc,
  3. Praha 2,
  4. Praha 5,
  5. Datteln,
  6. Erlangen,
  7. Frankfurt-Niederrad,
  8. Gauting,
  9. Oldenburg,
  10. Den Haag,
  11. Rotterdam,
  12. Bratislava,
  13. Lubochna,
  14. Goteborg,
  15. Goteborg,
  16. Linkoping,
  17. Umea,
  18. Sihhiye, Ankara
  19. Capa, Istanbul
  20. Salford, Manchester
  21. Glasgow,
  22. London,
  23. Norwich,
ALL GENDERS
4 Years+
years
MULTIPLE SITES
Growth Hormone DeficiencyIGF1 Generation Test
NCT00145457
  1. Besançon,
  2. Bordeaux,
  3. Dunkerque,
  4. Limoges Cedex,
  5. Nice,
  6. Paris Cedex 14,
  7. Tarbes,
  8. Toulouse Cedex 9,
ALL GENDERS
4 Years+
years
MULTIPLE SITES
Growth Hormone DeficiencyTransition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
NCT00156143
ALL GENDERS
15 Years+
years
MULTIPLE SITES
Growth Hormone DeficiencyPatient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD
NCT03831880
  1. Aurora, Colorado
  2. Sacramento, California
  3. Aurora, Colorado
  4. Centennial, Colorado
  5. Greenwood Village, Colorado
  6. Jacksonville, Florida
  7. Jacksonville, Florida
  8. Orlando, Florida
  9. Orlando, Florida
  10. Pensacola, Florida
  11. Tampa, Florida
  12. Atlanta, Georgia
  13. Atlanta, Georgia
  14. Indianapolis, Indiana
  15. Indianapolis, Indiana
  16. Boston, Massachusetts
  17. Boston, Massachusetts
  18. Boston, Massachusetts
  19. Kansas City, Missouri
  20. Hackensack, New Jersey
  21. Pittsburgh, Pennsylvania
  22. Chattanooga, Tennessee
  23. Chattanooga, Tennessee
  24. Memphis, Tennessee
  25. Fort Worth, Texas
  26. Fort Worth, Texas
  27. Fort Worth, Texas
  28. Seattle, Washington
  29. Tacoma, Washington
  30. Tacoma, Washington
  31. Sofia,
  32. Varna,
  33. Brno,
  34. Brno,
  35. Praha 5,
  36. Praha 5,
  37. Bratislava,
  38. Bratislava,
  39. Kosice,
  40. Kosice,
  41. Glasgow,
  42. Glasgow,
  43. Glasgow,
  44. London,
  45. London,
  46. London,
  47. London,
  48. London,
ALL GENDERS
3 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency
Official Title  ICMJE A Double Blind, Single Dose Study To Explore The Safety, Pharmacokinetics And Pharmacodynamics Of PHA-794428 In Pediatric Patients With Growth Hormone Deficiency
Brief Summary This will be the first clinical study of the development of PHA-794428 in a pediatric population. Since differences in PK and/or PD response may occur between adult and pediatric subjects, it is deemed appropriate to first conduct an exploratory single dose study in pediatric patients to assess safety and tolerability in this patient population. In addition this will add pediatric data to facilitate the prediction of the optimal therapeutic dose to be tested in repeated dose phase 2b trials in children, using PK/PD modeling
Detailed Description The study terminated on 10-Dec-2007. Pfizer's decision to terminate the program was due to cases of injection-site lipoatrophy that were reported in the clinical Phase 2 studies after a single injection of PHA 794428.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Growth Hormone Deficiency
Intervention  ICMJE Drug: PHA-794428
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: April 13, 2006)
32
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE November 2007
Actual Primary Completion Date November 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • 1.Male and female children with a minimum age of 6 years
  • 2. Prepubertal as defined by Tanner staging
  • 3. Growth hormone deficiency

Exclusion Criteria:

  • 1. PGHD patients with uncontrolled pituitary tumor growth
  • 2. Tumors within 3 mm of the optic chiasm
  • 3. Serum ALT and/or AST >= 1.5 times the upper limit of normal range
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 6 Years to 12 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   France,   Germany,   Israel,   United Kingdom
Removed Location Countries Spain
 
Administrative Information
NCT Number  ICMJE NCT00314938
Other Study ID Numbers  ICMJE A6391004
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP